{
    "medicine_id": "4f015a444cad99b45cf609231de14f5f78cc9554",
    "platform_id": "DB04960",
    "metadata": {
        "name": "Potiga 50 mg 1 Tablet film coated",
        "composition": "50 mg 1 Tipifarnib",
        "clinical_particulars": {
            "therapeutic_indications": "Investigated for use treatment in colorectal cancer leukemia myeloid pancreatic cancer and solid tumors",
            "contraindications": {
                "disease": "NA",
                "pregnancy": "NA",
                "machine_ops": "NA",
                "pharmacodynamics": "R115777 a nonpeptidomimetic farnesyl transferase inhibitor suppresses the growth of human pancreatic adenocarcinoma cell lines This growth inhibition is associated with modulation in the phosphorylation levels of signal transducers and activators of transcription 3 STAT3 and extracellular signal regulated kinases ERK",
                "excipients": "NA",
                "incompatibilities": [
                    {
                        "drugbank-id": "DB00012",
                        "description": "The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Tipifarnib"
                    },
                    {
                        "drugbank-id": "DB00016",
                        "description": "The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Tipifarnib"
                    },
                    {
                        "drugbank-id": "DB08894",
                        "description": "The risk or severity of Thrombosis can be increased when Peginesatide is combined with Tipifarnib"
                    },
                    {
                        "drugbank-id": "DB09107",
                        "description": "The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol epoetin beta is combined with Tipifarnib"
                    }
                ]
            }
        },
        "revision_date": "2023-05-14"
    }
}